must be on background lipid lowering treatment.

must be at high risk of a cv event.

must have an ldl c >/=70 mg/dl (1.8 mmol/l) and < 100 mg/dl (2.6 mmol/l) or non-hdl-c >/= 100 mg/dl (2.6 mmol/l) and < 130 mg/dl (3.4 mmol/l).

an ldl c < 70 mg/dl (1.8 mmol/l) or >/= 100 mg/dl (2.6 mmol/l) or non hdl-c < 100 mg/dl (2.6 mmol/l) or >/=130 mg/dl (3.4 mmol/l).

planned coronary (pci or cabg) or other arterial revascularization.

new york heart association class iv congestive heart failure or left ventricular ejection fraction < 25% by cardiac imaging.

chronic renal insufficiency with creatinine clearance of <30 ml/min/1.73m^2 by mdrd formula or with end state renal disease on dialysis.

history of hemorrhagic stroke.

prior exposure to bococizumab or other investigational pcsk9 inhibitor.